DK1377320T3 - Polynukleotidbindingskomplekser omfattende steroler og saponiner - Google Patents

Polynukleotidbindingskomplekser omfattende steroler og saponiner

Info

Publication number
DK1377320T3
DK1377320T3 DK02759762T DK02759762T DK1377320T3 DK 1377320 T3 DK1377320 T3 DK 1377320T3 DK 02759762 T DK02759762 T DK 02759762T DK 02759762 T DK02759762 T DK 02759762T DK 1377320 T3 DK1377320 T3 DK 1377320T3
Authority
DK
Denmark
Prior art keywords
complexes
saponins
sterols
methods
determinant
Prior art date
Application number
DK02759762T
Other languages
English (en)
Inventor
Kristian Dalsgaard
Nikolai Soeren Kirkby
Original Assignee
Nordic Vaccine Technology As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nordic Vaccine Technology As filed Critical Nordic Vaccine Technology As
Application granted granted Critical
Publication of DK1377320T3 publication Critical patent/DK1377320T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
DK02759762T 2001-04-04 2002-04-04 Polynukleotidbindingskomplekser omfattende steroler og saponiner DK1377320T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200100560 2001-04-04
US30860901P 2001-07-31 2001-07-31
PCT/DK2002/000229 WO2002080981A2 (en) 2001-04-04 2002-04-04 Polynucleotide binding complexes comprising sterols and saponins

Publications (1)

Publication Number Publication Date
DK1377320T3 true DK1377320T3 (da) 2009-02-09

Family

ID=26069002

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02759762T DK1377320T3 (da) 2001-04-04 2002-04-04 Polynukleotidbindingskomplekser omfattende steroler og saponiner

Country Status (7)

Country Link
EP (2) EP2011517A1 (da)
JP (2) JP2004528321A (da)
AT (1) ATE409495T1 (da)
DE (1) DE60229118D1 (da)
DK (1) DK1377320T3 (da)
NZ (1) NZ529347A (da)
WO (1) WO2002080981A2 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003269839B2 (en) * 2002-10-02 2006-07-27 Nordic Vaccine A/S Composition for vaccination
WO2009106085A1 (en) * 2008-02-28 2009-09-03 Nordic Vaccine A/S Vaccine compositions comprising saccharide antigens
US10047116B2 (en) 2011-10-03 2018-08-14 Mx Adjuvac Ab Nanoparticles, process for preparation and use thereof as carrier for amphipatic and hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
US9907846B2 (en) 2013-04-01 2018-03-06 Mx Adjuvac Ab Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
US11708388B2 (en) 2017-07-11 2023-07-25 Freie Universität Berlin Uses of a saponin and method for its isolation
CN108498376B (zh) * 2018-04-02 2020-11-13 榛硕（武汉）智能科技有限公司 一种甲基硅油乳液及其制备方法
CN109295080B (zh) * 2018-09-19 2021-08-20 昆明理工大学 珠子参β-香树脂醇合成酶基因Pjβ-AS的用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4162282A (en) 1976-04-22 1979-07-24 Coulter Electronics, Inc. Method for producing uniform particles
GB2064320B (en) 1979-10-13 1983-10-12 Welsh Nat School Med Intra-ocular irrigation fluid
US4310505A (en) 1979-11-08 1982-01-12 California Institute Of Technology Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances
US4533254A (en) 1981-04-17 1985-08-06 Biotechnology Development Corporation Apparatus for forming emulsions
US4550022A (en) 1981-10-05 1985-10-29 Alcon Laboratories, Inc. Tissue irrigating solution
US4443432A (en) 1981-10-05 1984-04-17 Alcon Laboratories, Inc. Ophthmalic irrigating solution
US4526714A (en) 1982-12-13 1985-07-02 Cordis Europa N.V. Conjugates of anticoagulant and protein
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE450674B (sv) 1982-11-17 1987-07-13 Volvo Ab Kabelholje
US4728575A (en) 1984-04-27 1988-03-01 Vestar, Inc. Contrast agents for NMR imaging
CA1264668A (en) 1984-06-20 1990-01-23 Pieter R. Cullis Extrusion techniques for producing liposomes
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
NZ217844A (en) 1985-10-11 1989-10-27 Sumitomo Pharma A sustained release pharmaceutical composition containing silicone elastomer and an albumin
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
IL79559A0 (en) 1986-07-29 1986-10-31 Univ Ramot Contrast agents for nmr medical imaging
US4728578A (en) 1986-08-13 1988-03-01 The Lubrizol Corporation Compositions containing basic metal salts and/or non-Newtonian colloidal disperse systems and vinyl aromatic containing polymers
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US4938970A (en) 1987-02-06 1990-07-03 Hustead Robert E Painless electrolyte solutions
US5583112A (en) 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
JPH04501723A (ja) 1988-11-09 1992-03-26 アンガー，エヴァン，シー． リポソーム性放射線造影剤
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
CA2064194A1 (en) 1989-07-27 1991-01-28 Nelson Teng Lipid a analog/immunogenic carrier conjugates and the use thereof as vaccines
NL9002314A (nl) 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
GB9106673D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
JPH06507904A (ja) 1991-05-23 1994-09-08 イマアーレクス・フアーマシユーチカル・コーポレーシヨン 磁気共鳴画像形成用の油脂可溶化合物
SE502569C2 (sv) * 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
US5650398A (en) 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
US5273965A (en) 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
AU1077795A (en) 1993-09-30 1995-04-18 Seed Capital Investments (Sci) B.V. Compounds with adjuvant activity
EP0904100B1 (en) * 1996-02-09 2006-07-26 Pi-Wan Cheng Cationic lipid and receptor ligand-facilitated delivery of biologically active molecules
BR9709993A (pt) 1996-06-25 1999-08-10 Stichting Inst Dierhouderij Vacina preparação de vacina composição processo para produção de uma preparação imugênica e preparação imugênica
JP3963506B2 (ja) * 1996-08-26 2007-08-22 俊彦 松尾 リポソーム点眼剤
AUPO517897A0 (en) * 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
JP2002505665A (ja) * 1997-04-30 2002-02-19 メリュー・オラバックス Ｔｈ１型アジュバントを含有する抗ヘリコバクターワクチン組成物
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
AUPO732997A0 (en) * 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
DE19740092A1 (de) * 1997-09-12 1999-03-18 Ulrich Dr Med Hengge Liposomen und Verfahren zur Transfektion von Zellen
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
PL351487A1 (en) * 1999-03-02 2003-04-22 Liposome Co Inc Encapsulation of bioactive complexes in liposomes
WO2001072331A1 (en) 2000-03-31 2001-10-04 Vaccine Chip Technology Aps Immunostimulating properties of a fragment of tgf-beta

Also Published As

Publication number Publication date
EP2011517A1 (en) 2009-01-07
DE60229118D1 (de) 2008-11-13
EP1377320B1 (en) 2008-10-01
JP2004528321A (ja) 2004-09-16
JP2010180249A (ja) 2010-08-19
WO2002080981A3 (en) 2002-12-19
NZ529347A (en) 2008-01-31
WO2002080981A2 (en) 2002-10-17
ATE409495T1 (de) 2008-10-15
EP1377320A2 (en) 2004-01-07

Similar Documents

Publication Publication Date Title
EP2301531A3 (en) Combinations and modes of administration of therapeutic agents and combination therapy
MXPA05006940A (es) Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.
WO2005025508A3 (en) Magnetically targetable particles comprising magnetic components and biocompatible polymers for site-specific delivery of biologically active agents
ATE355065T1 (de) Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika
EP2322215A3 (en) Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
WO2005051429A3 (en) Targeted conjugates with a modified saccharide linker
NO20053424D0 (no) Forbedrede farmasoytiske botulinumtoksin-preparater.
WO2005072061A3 (en) Conjugates for cancer therapy and diagnosis
BR0109704A (pt) Método de tratamento usando conjugados de imunógeno ligando
RU95109905A (ru) Композиции в жидком, полутвердом, твердом, гелеобразном или пастообразном виде и способ лечения заболеваний полости рта
HU0102039D0 (en) Use of paclitaxel stabilized with albumin for the preparation of pharmaceutical compositions treating solid tumors and the pharmaceutical compositions obtained thereby
IL173481A0 (en) Polysaccharide double-layer microcapsules as carriers for biologically active substance oral administration
BRPI0510315A (pt) integração de vacinação com conjugado meningocócico
WO1999056723A3 (en) Hemoglobine-haptoglobin complexes for targeted drug delivery
DK1377320T3 (da) Polynukleotidbindingskomplekser omfattende steroler og saponiner
EP1491210A4 (en) THERAPEUTIC MEDICAMENT USING ANTIBODY PRESENTING HOLES PROTEIN NANOTEHICLES AND HIGH PROTEIN NANOTEHICLES
UA87877C2 (en) Pegylated liposomal doxorubicin in combination with ecteinescidin 743
DE60035192D1 (de) Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung
BR9912533A (pt) Composição farmacêutica tendo sabor melhorado
DK0559145T3 (da) Lægemiddel til truende abort
BG105924A (en) Composition for the treatment of psoriasis
EP1258248A3 (en) Tumor treatments comprising a fumagillol derivative and a further antineoplastic agent
FR2786699B1 (fr) Medicament destine notamment a prevenir ou traiter les dysfonctions sexuelles
DE60235549D1 (de) Pharmazeutische formulierung und darin enthaltende liganden; uea-1 mimetika
WO2002094183A3 (en) A method for tumor treatment with fumagillol derivatives